Publicaciones
2018
Histone modifications associated with biological drug response in moderate-to-severe psoriasisOvejero-Benito MC, Reolid A, Sánchez-Jiménez P, Saiz-Rodríguez M, Muñoz-Aceituno E, Llamas-Velasco M, Martín-Vilchez S, Cabaleiro T, Román M, Ochoa D, Daudén E, Abad-Santos F.
Exp Dermatol. 2018 Dec;27(12):1361-1371. doi: 10.1111/exd.13790.
2018
Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasisOvejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Talegón M, Cabaleiro T, Daudén E, Abad-Santos F.
Pharmacogenomics. 2018 Jan;19(1):7-16. doi: 10.2217/pgs-2017-0143. Epub 2017 Dec 1.
2018
Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe PsoriasisOvejero-Benito MC, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Abad-Santos F, Daudén E.
Am J Clin Dermatol. 2018 Apr;19(2):209-222. doi: 10.1007/s40257-017-0322-9.
2018
Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasisOvejero-Benito MC, Cabaleiro T, Sanz-García A, Llamas-Velasco M, Saiz-Rodríguez M, Prieto-Pérez R, Talegón M, Román M, Ochoa D, Reolid A, Daudén E, Abad-Santos F.
Br J Dermatol. 2018 Mar;178(3):798-800. doi: 10.1111/bjd.15504. Epub 2018 Jan 28.
